Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1242 | Discontinuation of ARB/ACEI Wiki | 1.00 |
| drug2384 | Mindfulness Alone (MO) Intervention Wiki | 1.00 |
| drug1025 | Continuation of ARB/ACEI Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The primary aim of this study is to examine the efficacy of a one-session, hour-long HIPAA-compliant video platform-based mindfulness + compassion telehealth intervention on reducing feelings of loneliness during COVID-19 quarantine. Participants (n=120) currently isolating due to COVID-19 will be randomized to one of three interventions: (a) mindfulness + compassion (MC); (b) mindfulness alone (MO); and (c) waitlist control (WL). The investigators predict that participants in the active intervention groups (mindfulness or mindfulness + compassion) will show a significantly greater reduction in subjective feelings of loneliness at one week follow-up compared to those in the waitlist control group. Additionally, investigators predict that participants in the active intervention groups will show a significantly greater reduction in stress at one week follow-up compared to those in the waitlist control group. Last, investigators predict that participants in the mindfulness + compassion group will show a significantly greater reduction in subjective feelings of loneliness at the 2-week follow-up follow-up relative to those in the mindfulness only group.
Description: Change from baseline in self-reported feelings of loneliness and social isolation. Scores range from 8 to 32, with higher scores indicating higher levels of loneliness.
Measure: Revised University of California Los Angeles Loneliness Scale - 8 (ULS-8) Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)Description: Change from baseline in self-reported feelings of stress. Scores range from 0 to 40, with higher scores indicating more perceived stress.
Measure: Perceived Stress Scale (PSS) Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)Description: Change from baseline in self-reported anxiety symptoms. Scores range from 0 to 21, with higher scores indicating more severe anxiety.
Measure: Generalized Anxiety Disorder - 7 (GAD-7) Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)Description: Change from baseline in self-reported depressive symptoms. Scores range from 0 to 24, with higher scores indicating higher depressive symptom severity.
Measure: Personal Health Questionnaire Depression Scale - 8 (PHQ-8) Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)Description: Change from baseline in self-reported quality of life. Scores range from 0 to 48, with higher scores indicating better quality of life.
Measure: Brunnsviken Brief Quality of Life Scale (BBQ) Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports